10 months, after which the mature striae become white and flat. Although striae are rare after breast augmentation, they can be disfiguring and devastating for the patient, especially because the procedure's goal is to improve cosmesis. To date, only 1 publication has addressed the incidence and risk factors of striae after breast augmentation; to our knowledge, all other reports have been case studies. We investigated our patient population to analyze multiple factors and deduce any possible correlations that cause striae after cosmetic breast augmentation. Enhanced understanding of the etiology will enable us to better inform our patients preoperatively about this potential complication.
MEthodS
This study was approved by the Institutional Review Board of the University of Texas Medical Branch in Galveston. A retrospective chart review was performed for patients who underwent primary cosmetic breast augmentation mammaplasty from 2005 to 2012 in a single-surgeon practice. Cases of augmentation mastopexy were excluded. One surgeon (C.L.M.) performed all procedures in the same clinical setting and placed either saline or silicone gel implants, all of which were from the same manufacturer (Mentor Worldwide LLC, Santa Barbara, California). All implants were moderate plus, smooth wall, round style, and all were placed in the dual-plane submuscular pocket.
After initial review of patients' medical records, it was noted that new-onset breast striae occurred only in patients aged ≤25 years. Therefore, inclusion criteria were all women ≤25 years of age who underwent primary breast augmentation for cosmetic purposes; 549 patients met these criteria and were included in the study. (Hence, patients who underwent secondary augmentation, augmentation mastopexy, or reconstruction were excluded.) Photographs of all patients were obtained pre-and postoperatively. Striae were determined to be present based on postoperative photographs and notes in the medical records. All photographs were examined by the surgeon who performed the operations (C.L.M.).
The potential risk factors examined included age, body mass index (BMI), oral contraceptive use, time of last menstrual period (LMP), parity, smoking and alcohol status, diabetes mellitus, and personal history of striae. Surgical and implant factors also were examined, including incision site, type of implant (silicone vs saline), volume of implant, implant placement location (subglandular vs submuscular), and the size and actual fill volume of saline implants.
The database was constructed and statistical analysis was performed with SAS version 9.3 (SAS Institute, Cary, North Carolina). Logistic regression was performed to assess whether the various risk factors would predict striae. Variables determined to be significant at the P < .05 level via univariate regression analysis were then examined by multivariate regression analysis. Relative risk was analyzed for significant variables. Age was subcategorized into single-year increments from 15 to 25 years. The BMI was defined as underweight (<18.5 kg/m 2 ), normal weight (18.5-24.9 kg/m 2 ), or overweight (>25 kg/m 2 ). The LMP was subcategorized as to whether the surgery occurred in the first half (days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] or second half (after day 14) of the menstrual cycle. Statistical significance was defined as P < .05.
RESuLtS
Mean follow-up time for the 549 patients was 13 months; 516 (94%) were underweight or normal weight, and 33 (6%) were overweight. Oral contraceptives were taken by 258 patients (47%). For 357 patients (65%), the first day of the LMP occurred >14 days before the surgery. It was noted that 285 patients (52%) were nulliparous compared with 264 (48%) who were at least primiparous. Only 11 patients (2%) had a history of striae. Implant data were as follows: 93 patients (17%) received silicone implants (mean volume, 446 cc; range, 250-800 cc), and 456 (83%) received saline implants (mean volume, 486 cc; range, 225-1000 cc; mean overfill, 75 cc). The mean implant volume was 479 cc. Overall, 159 patients (29%) were smokers, 1 had diabetes mellitus, and 214 (39%) were social alcohol drinkers (the remainder did not drink).
New-onset breast striae after breast augmentation were observed in 17 cases (3.10%). The risk of this complication was found to be statistically significant among the following subsets of patients: those who were 18 to 20 years old, were nulliparous, began their LMP >14 days before surgery, and had a personal history of striae. In this study, there was no association between striae formation and type of implant (silicone vs saline), incision site, implant location, history of smoking, diabetes mellitus, or alcohol use. On average, breast striae developed 57.71 days postoperatively (range, 30-90 days).
The risk of postoperative breast striae was significantly greater among younger patients (18-20 years of age; P = .0056), peaking at 9.77% of patients aged 19 years and decreasing to 1.42% of 25-year-olds ( Figure 1 ). The mean age of our cohort was 22 years, and the mean age for breast striae development was 21 years. Table 1 shows the percentage of patients in each age group who experienced striae and their relative risk for developing this complication. The relative risk of breast striae formation for an 18-to 20-year-old was 3.3 times greater than for patients of other ages.
Nulliparous patients were found to have a significant risk for breast striae (P = .0003). In our study, 16 (94.75%) of the 17 patients who developed striae were nulliparous ( Figure 2 ). For a nulliparous (vs multiparous) patient, the 1052 Aesthetic Surgery Journal 34 (7) risk of developing breast striae was 14.38 times greater. We did not collect data on parity status for women aged >25 years.
Patients whose LMP began >14 days before surgery (n = 357) had a statistically significant risk of developing breast striae (P = .05). In fact, not a single patient with breast striae in our study had her surgery in the first half of her menstrual cycle (Figure 3 ). The risk of breast striae development was 9.24 times higher for patients whose surgery occurred >14 days since their LMP began.
Patients with a history of striae anywhere else on their body (17 patients) also had a significant risk for breast striae after augmentation mammaplasty (P = .0391; Figure  4 ), and 2 (11.76%) of these patients developed breast striae. Patients with a history of striae anywhere on the body had a 6.11 times greater risk of postoperative breast striae. Five of the 532 patients who did not experience breast striae postoperatively already had striae somewhere else on their body. Although not statistically significant, there was a strong correlation between new-onset breast striae and implant size as well as BMI, specifically among underweight and normal-weight patients (P = .07; Figure 5 ). Analyses of implant size vs age ( Figure 6 ) and BMI vs striae formation ( Figure 7 ) revealed no significant differences. Only 1 patient was found to have diffuse striae of the entire breast; all others had more localized striae (Figures 8-11 ).
diScuSSion
Breast striae can be a morbid complication to an otherwise aesthetically pleasing augmented breast. Striae are believed to be dermal scars resulting from intrinsic stretching forces on soft tissues. Pinkus et al 4 were the first to describe the increase in elastic fibers in striae and compare it with scar tissue. Bhangoo et al 5 also observed elastogenesis in scar tissue. Ebert 6 and Breathnach 7 examined striae evolution, from early (striae rubrae) to late (striae albae) phases. Striae rubrae are characterized by inflammation with cuffing of small vessels by lymphocytes and monocytes accompanied by increased mast cells and active fibroblasts, which destroys collagen and elastic fibers. Striae albae are characterized by a mature, typical white stretch mark thought to be scar tissue resulting from the regeneration of collagen and elastic fibers in the direction imposed by mechanical forces. Healing takes place under tension and thus may result in linear and atrophic striae. Moreover, hair follicles and other appendages are absent due to the initial damage.
Zheng et al 2 observed mature striae tissue under microscopy. The epidermis over the striae was shown to be flattened and thinned, with an extremely dense packing of thin, eosinophilic collagen bundles in a parallel array, horizontal to the surface. These bundles replaced the papillary dermis located just underneath the epidermis. Elastic fibers were numerous, were densely packed, and had a fine parallel orientation to the surface, mimicking the collagen fibers. Cordeiro et al 8 recently examined hormonal receptors located within striae tissue under frozen processing, protein extraction, and Western blot assay; they noted a significant increase in hormonal receptors in comparison to normal tissue: 2.2-fold increase in estrogen receptors, 1.8-fold increase in androgen receptors, and 1.7-fold increase in glucocorticoid receptors. It is well known that estrogen and corticosteroid products interfere with the mechanisms of wound repair and extracellular matrix reorganization; they also reduce collagen synthesis and induce skin atrophy. These hormones have also been postulated to decrease adhesion between collagen fibers and increase ground substance with degranulation of mast cells, resulting in striae formation in areas of stretching. 9 Burrows and Lowell 10 suggested that striae develop more easily in skin that contains a high amount of rigid crosslinked collagen, which is common in early adulthood. Thomas and Liston 11 demonstrated that the prevalence of striae gravidarum was greater in younger adult obstetric patients. Maia et al 12 and Elsaie et al 13 also observed more striae in younger patients and suggested a relationship to skin stretching caused by microfibril damage to 
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Various underlying factors may contribute to the formation of striae. The exact pathogenesis is not known; rather, it has been considered multifactorial, involving mechanical, hormonal, and genetic factors. Rosenthal 14 proposed classifying striae according to 4 etiologic mechanisms: (1) insufficient development of the tegument, including a deficiency in its elastic properties; (2) rapid stretching of the skin; (3) endocrine imbalance; and (4) other, possibly toxic, causes.
Our finding that all patients with postoperative breast striae were ≤25 years of age correlates with findings of Burrows and Lowell 10 and Thomas and Liston 11 in younger adults. We believe that this may be attributable to a hormonal influence and to the characteristics of soft tissue in young adults. Growth hormone, estrogen, and dehydroepiandrosterone (DHEA)-the most abundant circulating steroid in the body and a precursor to many hormones-are at their highest levels between the ages of 18 and 25 years and decrease dramatically with age.
The common denominator for all of our significant findings is a strong hormonal influence. As noted, patients ≤25 years of age are exposed to higher levels of various hormones. It was surprising to discover that the LMP for 100% of our patients with postoperative breast striae had started more than 14 days before surgery, when progesterone levels are predominant and estrogen levels are moderate. Together with the findings of Cordeiro et al, 8 who noted increased estrogen, androgen, and glucocorticoid receptors in striae tissue, our observations of increased risk associated with young age and higher overall estrogen, progesterone, or growth hormone levels indicate that breast striae formation correlates strongly with hormonal influences. In addition, a possible genetic component is suggested by the significant association between personal history of striae and higher risk of new-onset breast striae in our study.
Our findings confirm those of Basile et al 15 for striae distensae after breast augmentation; 4.6% of their patients developed striae, and increased risk was associated with nulliparity, use of oral contraception, being overweight, younger age (peak incidence at age 20 years), and personal history of stretch marks. To our knowledge, this is the only published study similar to ours. The fact that the LMP of all our patients with postoperative breast striae started >14 days before surgery may relate to the disproportionate number of patients (65%) who had surgery during this part of the menstrual cycle. A contributing factor may be oral contraceptive use, which would increase the duration between cycles. Furthermore, the strong correlation between nulliparity and striae formation may be attributable to selection bias, as women younger than 25 years are more likely to be nulliparous. We did not obtain data for older women and thus cannot deduce whether parity alone, without youth, may be protective. However, this factor alone probably does not account for the majority of the risk, and no nulliparous patient older than 25 years has developed striae in the senior surgeon's practice (C.L.M.).
According to a survey of the American Society for Aesthetic Plastic Surgery (ASAPS) conducted in 2007, 16 the mean implant size used by most surgeons (81%) ranges from 300 to 400 cc. Our mean size was 446 cc for silicone implants and 486 cc for saline implants. We initially hypothesized that a correlation would exist between implant size and the occurrence of breast striae, but our data showed no significant correlation. Our higher-thanaverage implant size may reflect a regional preference as well as the senior surgeon's practice of routinely overinflating saline implants by 15% beyond the size selected by the patient preoperatively, or similarly increasing the size of silicone implants, all with the patient's understanding and consent.
Our findings provide further evidence of a potentially significant hormonal influence in the development of breast striae after breast augmentation. Our primary goal is to better inform patients about this potential complication. To that end, our results provide a clearer picture of which breast augmentation patients have a greater risk for this complication, and we can now approximate this risk. The lack of detailed postoperative follow-up in our study is a limiting factor in terms of furthering patient education. We did not obtain patient satisfaction scores or document postoperative interviews for our patients with breast striae. It would be beneficial to obtain data on the degree to which patients are concerned about striae and the effects on daily life. Further investigation is needed to elucidate the underlying causes of breast striae and to minimize and ultimately prevent their occurrence.
concLuSionS
Breast striae after cosmetic breast augmentation is a concern for patients and surgeons. The etiology of breast striae appears to be multifactorial and includes mechanical, hormonal, and genetic factors. Our findings demonstrate a strong correlation between hormonal imbalance and newonset breast striae following cosmetic breast augmentation. The striae developed only in patients aged ≤25 years (peaking at age 19), all of whose last menses occurred >14 days before surgery, and there was a significant association with nulliparity. The greater likelihood of newonset striae in these patients may relate to higher exposure to estrogen, growth hormone, and steroid products and/or a greater preponderance of receptors that facilitate striae formation. A genetic component is suggested by the significant association with a history of striae elsewhere on the body. This information will serve to better educate and prepare patients during preoperative consultations.
